Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • Non-Hodgkin Lymphoma • Internal Medicine • CAR-T • Hematology • DLBCL
How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?
Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with primary refractory vs other relapsing disease?
Answer from: Medical Oncologist at Academic Institution
For those who relapse after first line therapy, treatment recommendations are dependent on the timing of relapse. For those who relapse within 12 months of completing first-line therapy and are fit, I would strongly consider referral to a center with CAR T-cell capabilities. As noted before, 5-year ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Approximately 50 to 60% of patients with BCL achieve and maintain complete remission after 1L therapy- thus, 30 to 40% have relapse and 10% have refractory disease. Treating these patients can be challenging and often requires >2L therapies. CAR T cells are approved for patients who relapse withi...